This study explores whether receipt of pharmaceutical industry-sponsored meals by physicians is associated with their prescribing the promoted brand-name drug at higher rates to Medicare beneficiaries.
This study uses Medicare Part D prescriptions claims data and Massachusetts physicians payment database data to evaluate associations between industry payments to physicians and prescribing of brand-name statins.
The Viewpoint discusses the effects of “patent trolls” on generic drug prices and availability.
This Special Communication characterizes the relationships that often exist between physicians and corporate leaders of medical and technical companies and details strategies to minimize insider trading on information gleaned from these relationships.
This Viewpoint describe the case of the commercial withdrawal of tositumomab as a cautionary tale of the weaknesses in our current drug-approval system.
A newly proposed US Food and Drug Administration guidance could undermine the agency's drug safety laws and regulations by allowing pharmaceutical companies to claim their drugs are less risky than stated in the approved label.
This historical analysis uses internal sugar industry documents to describe how the industry sought to influence the scientific debate over the dietary causes of coronary heart disease in the 1950s and 1960s.
This survey study examined the nature, extent, and perceived consequences of industry relationships among institutional review board members in academic health centers and compared the results with findings from 2005.
This cohort study of off-label use of prescription drugs assesses the risks for and prevalence of adverse drug events documented in the electronic health records of adults seeking medical treatment under a national health insurance system.